<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Aptos;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
font-size:12.0pt;
font-family:"Aptos",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
p.email-components, li.email-components, div.email-components
{mso-style-name:email-components;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Aptos",sans-serif;}
span.EmailStyle26
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;
mso-ligatures:none;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:460728622;
mso-list-template-ids:162147478;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\uf0b7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\uf0a7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\uf0a7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\uf0a7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\uf0a7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\uf0a7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\uf0a7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\uf0a7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif'> </span><span style='font-size:11.0pt;font-family:"Calibri",sans-serif'><o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p><div id=phLiveContent><div id=canvasDiv><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#EFEFEF'><tr><td width="100%" valign=top style='width:100.0%;padding:15.0pt 15.0pt 15.0pt 15.0pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:6.25in;background:white;border-collapse:collapse'><tr><td valign=top style='padding:0in 0in 0in 0in'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td width="100%" style='width:100.0%;padding:0in 0in 0in 0in'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><div><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0in 0in 0in 0in'><div><p class=MsoNormal align=center style='text-align:center'><img width=220 height=120 style='width:2.2916in;height:1.25in' id="_x0000_i1027" src="https://s21aeml01blkbsa02.blob.core.windows.net/emailimages/2025/9/p-MUUse5ZSIEidSn7H3nSXkA/1E0422A0-0084-446D-982E-93A0CCF12CE1/084d4f4f-5757-4946-8c78-4057da98cc53/d8311752-56ef-432a-b774-2a42f9fc54ea.png" alt="The Carroll Center for the Blind Logo"><o:p></o:p></p></div></td></tr></table></div></div></td></tr></table></td></tr></table></div></td></tr><tr><td valign=top style='padding:0in 0in 0in 0in'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr style='font-weight:inherit'><td width="100%" style='width:100.0%;background:#000DB4;padding:0in 0in 0in 0in'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#000DB4;border-collapse:collapse'><tr><td style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><div><p align=center style='text-align:center'><strong><span style='font-size:19.5pt;font-family:"Arial",sans-serif;color:white'>SpliceBio: Pioneering a Novel Gene Therapy for Stargardt Disease</span></strong><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><o:p></o:p></span></p></div></td></tr></table></td></tr></table></div></td></tr><tr><td valign=top style='padding:0in 0in 0in 0in'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr style='font-weight:inherit'><td width="100%" valign=top style='width:100.0%;padding:0in 0in 0in 0in'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border-spacing: 0px;border-color:rgba(0, 0, 0, 0)'><tr><td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><div style='margin-bottom:12.0pt'><p><span style='font-family:"Arial",sans-serif;color:#333333'>Tune in <strong><span style='font-family:"Arial",sans-serif'>next Thursday, October 2</span></strong> to learn more about a promising new gene therapy for Stargardt disease, currently being developed by SpliceBio.</span><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><o:p></o:p></span></p><p><span style='font-family:"Arial",sans-serif;color:#333333'>SB-007 is designed to address the root cause of Stargardt disease and is now being evaluated in clinical trials. Whether you are living with Stargardt, supporting someone who is, or working in the field, this is a valuable opportunity to learn, engage, and ask questions directly to the SpliceBio team.</span><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><o:p></o:p></span></p></div><div align=right><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0in 0in 0in 0in'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=right style='border-collapse:collapse;margin-left:7.5pt'><tr><td style='padding:0in 0in 0in 0in'><p class=MsoNormal><img width=180 height=120 style='width:1.875in;height:1.25in' id="_x0000_i1026" src="https://s21aeml01blkbsa02.blob.core.windows.net/emailimages/2025/9/p-MUUse5ZSIEidSn7H3nSXkA/1E0422A0-0084-446D-982E-93A0CCF12CE1/897ab718-d4f2-48ff-8ca8-7d62568b723b/922baeb2-ea2d-43f2-9872-3c044fdf45f2.png" alt="SpliceBio logo"><o:p></o:p></p></td></tr></table><p><strong><span style='font-family:"Arial",sans-serif;color:#333333'>Event Details</span></strong><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><o:p></o:p></span></p><p><strong><span style='font-family:"Arial",sans-serif;color:#333333'>Date: </span></strong><span style='font-family:"Arial",sans-serif;color:#333333'>Thursday, October 2, 2025<br><strong><span style='font-family:"Arial",sans-serif'>Time:</span></strong> 12:00\u20131:00 PM ET<br><strong><span style='font-family:"Arial",sans-serif'>Location:</span></strong> Zoom (link provided upon registration)<br><strong><span style='font-family:"Arial",sans-serif'>Cost: </span></strong>Free</span><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><o:p></o:p></span></p><p><strong><span style='font-family:"Arial",sans-serif;color:#333333'>What to Expect</span></strong><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><o:p></o:p></span></p><ul type=disc><li class=email-components style='color:#333333;mso-list:l0 level1 lfo1'><span style='font-family:"Arial",sans-serif'>Hear from SpliceBio representatives about the principles of gene therapy.<o:p></o:p></span></li><li class=email-components style='color:#333333;mso-list:l0 level1 lfo1'><span style='font-family:"Arial",sans-serif'>Learn how SB-007 offers a novel approach to treatment.<o:p></o:p></span></li><li class=email-components style='color:#333333;mso-list:l0 level1 lfo1'><span style='font-family:"Arial",sans-serif'>Get details on the ongoing clinical studies.<o:p></o:p></span></li></ul><p><strong><span style='font-family:"Arial",sans-serif;color:#333333'>This webinar will be recorded</span></strong><span style='font-family:"Arial",sans-serif;color:#333333'> and made available on <a href="https://eml-pusa01.app.blackbaud.net/intv2/j/1E0422A0-0084-446D-982E-93A0CCF12CE1/r/1E0422A0-0084-446D-982E-93A0CCF12CE1_4062b737-637b-4898-9f11-6e8b03a9e875/l/6948457A-162F-4CBE-B047-A9FDFC29A629/c">our YouTube channel</a> after the event. Make sure to subscribe to receive a notification when the recording is available!</span><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><o:p></o:p></span></p><p><strong><span style='font-family:"Arial",sans-serif;color:#333333'>Questions?</span></strong><span style='font-family:"Arial",sans-serif;color:#333333'> Email <a href="mailto:development@carroll.org">development@car\u200broll.org</a> or call (617) 969-6200 ext. 236</span><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><o:p></o:p></span></p></div></td></tr></table></div></td></tr></table></td></tr></table></div></td></tr><tr><td valign=top style='padding:0in 0in 0in 0in'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr style='font-weight:inherit'><td width="100%" valign=top style='width:100.0%;padding:0in 0in 0in 0in'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border-spacing: 0px;border-color:rgba(0, 0, 0, 0)'><tr><td valign=top style='padding:0in 0in 0in 0in'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0in 0in 12.0pt 0in'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse'><tr><td style='background:#8D2C8A;padding:7.5pt 7.5pt 7.5pt 7.5pt;border-radius: 4px;box-shadow: none'><p class=MsoNormal align=center style='text-align:center'><span style='color:black'><a href="https://eml-pusa01.app.blackbaud.net/intv2/j/1E0422A0-0084-446D-982E-93A0CCF12CE1/r/1E0422A0-0084-446D-982E-93A0CCF12CE1_4062b737-637b-4898-9f11-6e8b03a9e875/l/D1BCEB69-44D6-48F6-B853-3047BEC0541A/c"><b><span style='font-size:18.0pt;font-family:"Arial",sans-serif;color:white;text-decoration:none'>Register Here</span></b></a> </span><o:p></o:p></p></td></tr></table></div></td></tr></table></div></td></tr></table></td></tr></table></div></td></tr><tr><td valign=top style='padding:0in 0in 0in 0in'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr style='font-weight:inherit'><td width="100%" valign=top style='width:100.0%;padding:0in 0in 0in 0in'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border-spacing: 0px;border-color:rgba(0, 0, 0, 0)'><tr><td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><div><p><strong><span style='font-family:"Arial",sans-serif;color:black'>About the Speakers</span></strong><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:black'><o:p></o:p></span></p><p><strong><i><span style='font-family:"Arial",sans-serif;color:black'>John Tobin</span></i></strong><span style='font-family:"Arial",sans-serif;color:black'> has worked in the pharmaceutical/biotechnology sector for 30 years. He has dedicated a large part of his career to conducting gene therapy, clinical development programmes in Geographic Atrophy as well as in the treatment of inherited retinal diseases such as Choroideremia, and X-linked Retinitis Pigmentosa. John heads up the Clinical Operations division at SpliceBio where his primary focus has been to bring the novel gene therapy, SB-007, to Stargardt subjects via the ASTRA Clinical Trial that commenced in early 2025.</span><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:black'><o:p></o:p></span></p><p><strong><i><span style='font-family:"Arial",sans-serif;color:black'>Dr. Feride Sahin</span></i></strong><span style='font-family:"Arial",sans-serif;color:black'> is a medical doctor who has worked in the pharmaceutical industry for more than 25 years, with the last 15 years dedicated to ophthalmology. Throughout her career, she has focused on medical affairs and clinical development across a range of ophthalmic indications. She is currently Senior Director of Clinical Development at SpliceBio, where her primary focus is advancing innovative therapies for patients with high unmet medical needs in ophthalmology.</span><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:black'><o:p></o:p></span></p></div></td></tr></table></td></tr></table></div></td></tr><tr><td valign=top style='padding:0in 0in 0in 0in'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td width="100%" valign=top style='width:100.0%;background:#DDDDDD;padding:0in 0in 0in 0in'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border-spacing: 0px;border-color:rgba(0, 0, 0, 0)'><tr><td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0in 0in 0in 0in'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse'><tr><td style='padding:.75pt .75pt .75pt .75pt'><div><p class=MsoNormal align=center style='text-align:center;background:#DDDDDD'><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><a href="https://eml-pusa01.app.blackbaud.net/intv2/j/1E0422A0-0084-446D-982E-93A0CCF12CE1/r/1E0422A0-0084-446D-982E-93A0CCF12CE1_4062b737-637b-4898-9f11-6e8b03a9e875/oo" target="_blank">Unsubscribe</a> <o:p></o:p></span></p></div></td></tr><tr><td style='padding:.75pt .75pt .75pt .75pt'><div><p class=MsoNormal align=center style='text-align:center;background:#DDDDDD'><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><a href="https://eml-pusa01.app.blackbaud.net/intv2/j/1E0422A0-0084-446D-982E-93A0CCF12CE1/r/1E0422A0-0084-446D-982E-93A0CCF12CE1_4062b737-637b-4898-9f11-6e8b03a9e875/l/BA63B3C6-FF33-4455-B827-86F27CD17BAC/c"><span style='color:#333333'>The Carroll Center for the Blind</span></a> <o:p></o:p></span></p></div></td></tr><tr><td style='padding:.75pt .75pt .75pt .75pt'><div><p class=MsoNormal align=center style='text-align:center;background:#DDDDDD'><span style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#333333'><a href="https://www.carroll.org">https://www.carroll.org</a> <o:p></o:p></span></p></div></td></tr></table></div></td></tr></table></div></td></tr></table></td></tr></table></div></td></tr><tr><td style='padding:0in 0in 0in 0in'></td></tr></table></div></td></tr></table></div></div></div><p class=MsoNormal><img src="data:image/gif;base64,R0lGODlhAQABAJEAAP///wAAAAAAAAAAACH5BAkAAAAALAAAAAABAAEAAAgEAAEEBAA7" width="1" height="1" alt="Web Bug from https://eml-pusa01.app.blackbaud.net/intv2/j/1E0422A0-0084-446D-982E-93A0CCF12CE1/r/1E0422A0-0084-446D-982E-93A0CCF12CE1_4062b737-637b-4898-9f11-6e8b03a9e875/o" /><o:p></o:p></p></div></body></html>